A Single-Center, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose, Semi-Sequential Adaptive Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Basimglurant Following Oral Administration in Healthy Subjects and in Patients With Major Depressive Disorder

Trial Profile

A Single-Center, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose, Semi-Sequential Adaptive Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Basimglurant Following Oral Administration in Healthy Subjects and in Patients With Major Depressive Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Basimglurant (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Aug 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov
    • 31 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015 as per ClinicalTrials.gov record.
    • 31 Jul 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Sep 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top